Ignite Creation Date:
2024-05-06 @ 3:27 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04648709
Status:
TERMINATED
Last Update Posted:
2023-12-20
First Post:
2020-11-27
Brief Title:
Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Organization:
Centre Hospitalier Universitaire de Saint Etienne
Study Overview
Official Title:
Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19
Status:
TERMINATED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The development and generalisation of vaccination led to a significant drop in the number of patients meeting the inclusion criteria
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVIMMUNITY
Brief Summary:
Current data in the literature demonstrate that the immune response to CoV-2-SARS is much more complex than initially assumed In fact beyond the humoral response including the existence of neutralizing CAs the adaptive lymphocyte T-type immune response also appears to play an important role in controlling the infection and reducing the severity of the disease At this stage the analysis of this T response is still rudimentary and underdeveloped but it seems crucial to be able to analyze it effectively in COVID-19 patients which could help predict the evolution of the infection It is also currently difficult to know the evolution of this response over time and especially after the resolution of the infection
To this end we will analyze the T lymphocyte response ELISPOT and QUANTIFERON based on the secretion of IFN Th1 and IL-4 Th2 by CoV-2-SARS specific T cells from COVID-19 patients We will compare the T response to the quality of the systemic and mucosal humoral response Finally we will evaluate in parallel two new biomarkers of the severity of COVID-19 plasma calprotectin and the presence of antibodies to type 1 IFN antibodies
To this end we will analyze the T lymphocyte response ELISPOT and QUANTIFERON based on the secretion of IFN Th1 and IL-4 Th2 by CoV-2-SARS specific T cells from COVID-19 patients We will compare the T response to the quality of the systemic and mucosal humoral response Finally we will evaluate in parallel two new biomarkers of the severity of COVID-19 plasma calprotectin and the presence of antibodies to type 1 IFN antibodies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-A02943-36 | OTHER | ANSM | None |